USD 7.41
(19.71%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 786.9 Million USD | -19.89% |
2022 | 392.62 Million USD | 38.51% |
2021 | 283.46 Million USD | -10.27% |
2020 | 315.9 Million USD | 93.11% |
2019 | 163.58 Million USD | 48.11% |
2018 | 110.44 Million USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 75.87 Million USD | -0.83% |
2024 Q3 | 70.06 Million USD | -7.65% |
2024 Q1 | 76.5 Million USD | 7.06% |
2023 Q3 | 85.93 Million USD | -6.02% |
2023 FY | 314.51 Million USD | -19.89% |
2023 Q1 | 92.26 Million USD | -6.26% |
2023 Q2 | 91.43 Million USD | -0.9% |
2023 Q4 | 71.45 Million USD | -16.84% |
2022 Q2 | 97.42 Million USD | -0.54% |
2022 Q1 | 97.94 Million USD | 28.08% |
2022 Q3 | 98.82 Million USD | 1.44% |
2022 Q4 | 98.42 Million USD | -0.41% |
2022 FY | 392.62 Million USD | 38.51% |
2021 Q2 | 63.86 Million USD | 5.33% |
2021 Q4 | 76.47 Million USD | -7.29% |
2021 Q3 | 82.48 Million USD | 29.17% |
2021 FY | 283.46 Million USD | -10.27% |
2021 Q1 | 60.63 Million USD | -15.99% |
2020 FY | 315.9 Million USD | 93.11% |
2020 Q4 | 72.17 Million USD | -14.81% |
2020 Q3 | 84.72 Million USD | -24.74% |
2020 Q2 | 112.57 Million USD | 142.42% |
2020 Q1 | 46.43 Million USD | 4.1% |
2019 FY | 163.58 Million USD | 48.11% |
2019 Q4 | 44.6 Million USD | 7.66% |
2019 Q3 | 41.43 Million USD | 5.21% |
2019 Q2 | 39.38 Million USD | 3.2% |
2019 Q1 | 38.16 Million USD | 0.0% |
2018 FY | 110.44 Million USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Doximity, Inc. | 260.87 Million USD | -201.64% |
Evolent Health, Inc. | 531.68 Million USD | -48.003% |
MultiPlan Corporation | 564.07 Million USD | -39.504% |
Phreesia, Inc. | 369.84 Million USD | -112.768% |
Teladoc Health, Inc. | 2.09 Billion USD | 62.366% |
Veeva Systems Inc. | 1.25 Billion USD | 37.401% |